← Eichor
Study identifier: NCT07260071 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease

Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD  ·  Sponsor: King's College London

PhaseN/A
Planned participants200
Who can joinAll sexes, 12 Years to 17 Years
Healthy volunteersNo

About this study

The goal of this project is to measure the prevalence of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and hypertension in the general population of children and young people at risk of ADPKD, using magnetic resonance imaging (MRI) for rapid diagnosis alongside genetic testing. The main question it aims to answer is: What is the prevalence of hypertension in a population sample of adolescents with ADPKD? Participants will have the following measurements performed: * Height and weight. * Blood pressure. * Non-invasive measurement of arterial stiffness. * Cardiac and renal MRI. * Blood sample. * Genetic testing.

This description comes directly from the study's public registry record.

Talk to the study team

Benjamin Boxer, PhD  ·  +44 20 7188 4770  ·  gstt.hiya.pkd@nhs.net

Louise Keehn, MSc  ·  +44 20 7188 4770  ·  louise.keehn@kcl.ac.uk

Always discuss trial participation with your own doctor first.

Locations (1)

Evelina London Children's HospitalLondon, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07260071